Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.32 |
| ▸ | ODC1 | P11926 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205332 | 0.86 | GLRA1 (0.37) | GLRA1SLC6A9OR51E2 | |
| SCHEMBL825611 | 0.83 | SMN1; SMN2 (0.42) | GLRA1SLC6A9OR51E2SMN1; SMN2HIF1A | |
| SCHEMBL8601948 | 0.80 | SMN1; SMN2 (0.34) | SMN1; SMN2HIF1AARG1ARG2ODC1 | |
| SCHEMBL2007928 | 0.80 | SMN1; SMN2 (0.39) | SMN1; SMN2HIF1AARG1ARG2ODC1 | |
| SCHEMBL4361740 | 0.80 | MEN1 (0.39) | GLRA1SLC6A9OR51E2SMN1; SMN2HIF1A | |
| SCHEMBL619053 | 0.80 | TSHR (0.35) | SMN1; SMN2HIF1AARG1ARG2 | |
| SCHEMBL9324958 | 0.78 | SMN1; SMN2 (0.33) | GLRA1SLC6A9OR51E2SMN1; SMN2HIF1A | |
| SCHEMBL439437 | 0.78 | SMN1; SMN2 (0.33) | GLRA1SLC6A9OR51E2SMN1; SMN2HIF1A | |
| SCHEMBL11211091 | 0.77 | THRB (0.45) | GLRA1SLC6A9OR51E2SMN1; SMN2HIF1A | |
| SCHEMBL8991294 | 0.77 | SMN1; SMN2 (0.32) | SMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778871-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| EP-1577323-B1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8361968-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20120015868-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20090318365-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090298765-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-03 | — | — | US | disclosed |
| US-7625869-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-01 | — | — | US | disclosed |
| EP-2113513-A2 | Metastin derivatives and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1758932-A2 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-20060241051-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-26 | — | — | US | disclosed |
| WO-2006001499-A2 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | WO | disclosed |
| EP-1577323-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015868-A1 | Metastin derivatives and use thereof | MET, HGFAC, HGF | GLRA1 4642/4885SLC6A9 3815/4885OR51E2 3431/4885 |
| US-20090318365-A1 | METASTIN DERIVATIVES AND USE THEREOF | MET, HGF, HGFAC | GLRA1 4666/4885SLC6A9 3768/4885OR51E2 3499/4885 |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | GNRHR, SHBG, MEN1 | GLRA1 4303/4885SLC6A9 3468/4885OR51E2 3067/4885 |
| US-20060241051-A1 | Metastin derivatives and use thereof | MET, HGFAC, HGF | GLRA1 4642/4885SLC6A9 3815/4885OR51E2 3431/4885 |
| US-20090298765-A1 | Metastin derivatives and use thereof | GNRHR, SHBG, MEN1 | GLRA1 4303/4885SLC6A9 3468/4885OR51E2 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.